HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  van der Groep, Petra ^a   van Diest, Paul J ^a   Smolders, Yvonne H C M ^a   Ausems, Margreet G E M ^a   van der Luijt, Rob B ^a   Menko, Fred H ^b   Bart, Joost ^c   de Vries, Elisabeth G E ^c   van der Wall, Elsken ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; ARTICLE; CAIX GENE; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MARKER; GENETIC RISK; GLUT 1 GENE; HETEROZYGOSITY; HIF 1ALPHA GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE BRCA2; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; ANOXIA; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS;

EID: 84873678183     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056055     Document Type: Article

References (60)

1. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-23.
2. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, et al. (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57: 1222-7.
3. Jönsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, et al. (2005) Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 65: 7612-21.
4. van Beers EH, van Welsem T, Wessels LFA, Li Y, Oldenburg RA, et al. (2005) Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 65: 822-7.
5. Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, et al. (2005) A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res 11: 1146-53.
6. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, et al. (2003) Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci U S A 100: 2532-7.
7. Wessels LF, van Welsem T, Hart AA, van't Veer LJ, Reinders MJ, et al. (2002) Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62: 7110-7.
8. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, et al. (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310-8.
9. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, et al. (1996) Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77: 697-709.
10. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505-10.
11. Chappuis PO, Nethercot V, Foulkes WD, (2000) Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18: 287-95.
12. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, et al. (2003) Germline BRCA1 mutations and a basal epithelialphenotype in breast cancer. J Natl Cancer Inst 95: 1482-5.
13. Van der Groep P, Bouter A, van der Zanden R, Menko FH, Buerger H, et al. (2004) Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96: 712-3.
14. Van der Groep P, Bouter A, van der Zanden R, Siccema I, Menko FH, et al. (2006) Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 59: 611-7.
15. Bane AL, Pinnaduwage D, Colby S, Reedijk M, Egan SE, et al. (2009) Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 117: 183-91.
16. Vaupel P, Thews O, Hoeckel M, (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18: 243-59.
17. Salceda S, Caro J, (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-7.
18. Huang LE, Gu J, Schau M, Bunn HF, (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependert degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci 95: 7987-92.
19. Semenza GL, (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-78.
20. Semenza GL, Wang GL, (1992) A nuclear factor induced by hypoxia via de novo synthesis binds to the human erythropoeitin gene enhancer at a site required for transcriptational activation. Mol Cell Biol 12: 5447-54.
21. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, et al. (2003) Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast cancer. Cancer 97: 1573-81.
22. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, et al. (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93: 309-14.
23. Bos R, van der Hoeven JJM, van der Wall E, van der Groep P, van Diest PJ, et al. (2002) Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20: 379-87.
24. Bos R, van Diest PJ, van der Groep P, Greijer AE, Hermsen MAJA, et al. (2003) Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1α (HIF-1α). Oncogene 22: 8948-51.
25. Bos R, van Diest PJ, van der Groep P, Shvarts A, Greijer AE, et al. (2004) Expression of hypoxia-inducible factor-1 alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res 6: R450-R9.
26. Bos R, Van Diest PJ, De Jong JS, Van der Groep P, Van der Valk P, et al. (2005) Hypoxia-inducible factor-1α is associated with angiogenesis and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46: 31-6.
27. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, et al. (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. J Clin Pathol 58: 172-7.
28. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, et al. (2007) HIF-1α and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer 120: 1451-8.
29. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-83.
30. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A, (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276: 9519-25.
31. Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, et al. (2006) BRCA1 plays a role in the hypoxic response by regulating HIF-1α stability and by modulating Vascular endothelial growth factor expression. J Biol Chem 281: 13047-56.
32. van der Groep P, Bouter A, Menko FH, van der Wall E, van Diest PJ, (2008) High frequency of HIF-1α overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat 111: 475-80.
33. Yan M, Rayoo M, Takano EA, (2009) KConFab Investigators (2009) Fox SB, (2009) BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. Br J Cancer 101: 1168-74.
34. Boecker W (2006) Preneoplasia of the breast. A New Conceptual Approach to Proliferative Breast Disease. Elsevier, Gmbh, Munich, p407-p467.
35. Sgroi DC, (2010) Preinvasive breast cancer. Annu Rev Pathol 5: 193-221.
36. Claus EB, Chu P, Howe CL, Davison TL, Stern DF, et al. (2001) Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 70: 303-16.
37. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, et al. (2008) Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13: 394-406.
38. van Diest PJ, (1999) Ductal carcinoma in situ in breast carcinogenesis. J Pathol 187: 383-4.
39. Claus EB, Petruzella S, Matloff E, Carter D, (2005) Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293: 964-9.
40. Hoogerbrugge N, Bult P, de Widt-Levert LM, Beex LV, Kiemeney LA, et al. (2003) High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 21: 41-5.
41. Hoogerbrugge N, Bult P, Bonenkamp JJ, Ligtenberg MJ, Kiemeney LA, et al. (2006) Numerous high-risk epithelial lesions in familial breast cancer. Eur J Cancer 42: 2492-8.
42. Kauff ND, Brogi E, Scheuer L, Pathak DR, Borgen PI, et al. (2003) Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 97: 1601-8.
43. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, et al. (2007) Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 25: 642-7.
44. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, et al. (2009) High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila) 2: 122-7.
45. van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, et al. (2009) Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. J Clin Pathol 62: 926-30.
46. Bussolati G, Bongiovanni M, Cassoni P, Sapino A, (2000) Assessment of necrosis and hypoxia in ductal carcinoma in situ of the breast: basis for a new classification. Virchows Arch 437 (4) (): 360-4.
47. Central Committee on Research involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek) (text in Dutch): http://www.ccmo-online.nl/main.asp?pid=10&sid=30&ssid=51.
48. van Diest PJ, (2002) No consent should be needed for using leftover body material for scientific purposes. BMJ 325: 648-51.
49. Van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, et al. (1992) Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum Pathol 23: 603-7.
50. Koh MY, Lemos R Jr, Liu X, Powis G, (2011) The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Res 71: 4015-27.
51. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, et al. (2008) Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 68: 9212-20.
52. Welsh SJ, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G, (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia inducible factor-1a. Mol Cancer Ther 3: 233-44.
53. Delmas C, End D, Rochaix P, Favre G, Toulas C, et al. (2003) The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res 9: 6062-8.
54. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y, (2005) Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1α, causing glycolysis shutdown and cell death. Cancer Res 65: 999-1006.
55. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z, (2005) The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433-41.
56. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, et al. (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65: 605-12.
57. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-75.
58. Ricker JL, Chen Z, Yang XP, Pribluda VS, Swartz GM, et al. (2004) 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10: 8665-73.
59. Galbán S, Kuwano Y, Pullmann R Jr, Martindale JL, Kim HH, et al. (2008) RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1α. Mol Cell Biol 28: 93-107.
60. Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M, (2008) miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci U S A 105: 20297-302.